We develop, commercialize and market a range of automated technologies for CAR-T and other cell-based therapies.
With revolutionary cell-based therapies for cancer approaching reality, CAR-T developers must address a key challenge: how to manufacture high-quality, clinical-grade CAR-T cells at scale to provide these groundbreaking treatments to as many patients as possible.
ThermoGenesis, our device division, is a leading developer of automated technologies for clinical biobanking, point-of-care cell-based therapeutics and cellular processing for immuno-oncology and other clinical applications.
Cesca Clinical, our therapeutics division, leverages our proprietary cellular processing technology platform to develop safe and efficacious point-of-care therapies targeting a broad range of indications with unmet medical needs, including osteoarthritis and critical limb ischemia. Our goal is to establish partnerships to further advance these promising programs. Learn More